Triple negative breast cancer (TNBC) is a highly aggressive and recurrent type of breast carcinoma that is associated with poor patient prognosis. Because of the limited efficacy of current treatments, new therapeutic strategies need to be developed. The CXCR4-CXCL12 chemokine signaling axis guides cell migration in physiological and pathological processes including breast cancer metastases. Although targeted therapies to inhibit the CXCR4-CXCL12 axis are under clinical experimentation, still no effective therapeutic approaches have been established to block CXCR4 in TNBC. To unravel the role of the CXCR4-CXCL12 axis in TNBC early metastasis formation, we used the zebrafish xenograft model. Importantly, we demonstrate that cross communication between the zebrafish and human ligands and receptors takes place and human tumor cells expressing CXCR4 initiate early metastatic events by sensing zebrafish cognate ligands at the metastatic site. Taking advantage of the conserved intercommunication between human tumor cells and the zebrafish host, we blocked TNBC early metastatic events by chemical and genetic inhibition of CXCR4 signaling. We used IT1t, a potent CXCR4 antagonist, and show for the first time its promising anti-tumor effects. In conclusion, we confirm the validity of the zebrafish as a xenotransplantation model and propose a pharmacological approach to target CXCR4 in TNBC.
Inhibition of cross-species CXCR4 signaling by the small molecule IT1t impairs triple negative breast cancer early metastases in zebrafish
Currently Viewing Accepted Manuscript - Newer Version Available
Claudia Tulotta, Cristina Stefanescu, Elena Beletkaia, Jeroen Bussmann, Katsiaryna Tarbashevich, Thomas Schmidt, B. Ewa Snaar-Jagalska; Inhibition of cross-species CXCR4 signaling by the small molecule IT1t impairs triple negative breast cancer early metastases in zebrafish. Dis Model Mech 2016; dmm.023275. doi: https://doi.org/10.1242/dmm.023275
Download citation file:
Advertisement
Sex matters in preclinical research
DMM calls for improved inclusion, analysis and reporting of sex as a biological variable in preclinical animal modelling research. Read the full Editorial by Monica J. Justice.
Subject collection: Building advocacy into research
DMM’s new series - Building advocacy into research - features interviews, ‘The Patient’s Voice’, with patients and advocates for a range of disease types, with the aim of supporting the highest quality research for the benefit of all patients affected by disease.
Travelling Fellowships for early-career researchers
DMM and its sister journals offer Travelling Fellowships of up to £3,000 to graduate students and post-doctoral researchers wishing to make collaborative visits to other laboratories. Find out more about our Travelling Fellowships and read stories from previous grant recipients.
Read & Publish Open Access publishing: what authors say
We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
The Forest of Biologists
Our Publisher Claire Moulton recently visited the two Woodland Trust UK sites where we are planting new native trees for published Research and Review papers and protecting ancient woodland on behalf of our peer reviewers.
Other journals from
The Company of Biologists